AI Model for Accurate Fetal Age Estimation Developed in India

Researchers at IIT Madras and THSTI have developed Garbhini-GA2, the first AI model specifically designed for the Indian population to accurately estimate fetal age in the second and third trimesters. This is crucial because currently used models based on Western data can be inaccurate for Indian women, leading to improper care and imprecise delivery dates.

  • First-of-its-kind: Researchers at IIT Madras and THSTI have developed Garbhini-GA2, the first AI model specifically designed for the Indian population to accurately estimate fetal age in the second and third trimesters.
  • Improved Accuracy: This model addresses the limitations of using Western population data for gestational age estimation in India, leading to reduced errors by almost three times. This translates to better care for pregnant women and more precise delivery date prediction.
  • Potential Impact: Garbhini-GA2 has the potential to improve the care provided by doctors, ultimately reducing maternal and infant mortality rates in India. Once validated further, it could be deployed in clinics across the country.

A team from the Indian Institute of Technology (IIT) Madras and the Translational Health Science and Technology Institute (THSTI) has made a significant breakthrough in healthcare. They have developed Garbhini-GA2, the first AI model specifically designed for the Indian population to accurately estimate fetal age during the second and third trimesters.

Currently, doctors rely on formulas developed for Western populations, leading to potential errors when applied to Indian patients. Garbhini-GA2 addresses this problem by incorporating data specific to the Indian population. This results in almost three times lower error rates compared to existing methods, which translates to better prenatal care and more precise delivery date estimations for expecting mothers.

This innovation has the potential to significantly improve maternal and infant health outcomes in India. Garbhini-GA2, once further validated, could be deployed in clinics nationwide, empowering doctors with a more accurate tool for patient care. Additionally, this research contributes to the “GARBH-Ini” program, a government initiative aiming to reduce adverse pregnancy outcomes.